Oncology

Latest News

Top 5 Most-Read Oncology Content of 2024

December 25th 2024

This year’s most-read oncology content of 2024 includes topics on clinical trials, drug access, vaping and lung cancer, and more!

Most Popular Articles of 2024 in Evidence-Based Oncology

By Mary Caffrey

December 23rd 2024

ICYMI: Highlights From ASCO 2024

By Pearl Steinzor

December 21st 2024

chemotherapy | Image credit: Penn Medicine

The High Cost of Shortages of Low-Cost Chemotherapy

By Interview by Mary Caffrey

December 19th 2024

Leukemia diagnosis | Image credit: Vitalii Vodolazskyi - stock.adobe.com

Real-World Treatment Sequences and Cost Analysis of cBTKis in CLL

By Pearl Steinzor

December 17th 2024

Join this panel as they discuss treatment for metastatic NSCLC patients without driver mutations.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

January 20th 2017

Dr Richard Pazdur Confirmed Director of FDA's Oncology Center of Excellence

Surabhi Dangi-Garimella, PhD

Outgoing FDA Commissioner Robert Califf, MD, has announced that Richard Pazdur, MD, who was serving as the interim director, will now be heading the Oncology Center of Excellence.

January 20th 2017

This Week in Managed Care: January 20, 2017

This week, the top managed care stories included news that Republicans will introduce legislation to replace the Affordable Care Act, a report found the abortion rate hit a historic low, and results showed Januvia is safe for the oldest patients, even if they have cardiovascular risk.

January 20th 2017

ASH "Choosing Wisely Champions" Share Their Practice-Changing Success

Surabhi Dangi-Garimella, PhD

At the 2016 annual meeting, the American Society of Hematology introduced the “Choosing Wisely Champions” to recognize the efforts of practitioners who are working to eliminate costly and potentially harmful overuse of tests and procedures.

January 20th 2017

Precision Genomic Panels a Vital Clinical Support Tool in Pediatric Brain Tumors

Surabhi Dangi-Garimella, PhD

A collaborative study has concluded that genomic assays can be successfully used to identify diagnostic, prognostic, and treatment-relevant alterations and can help guide precision treatment decisions for pediatric brain tumors.

January 18th 2017

Prior Ibrutinib Treatment Improves CAR T-Cell Expansion, Could Impact Response in CLL

Surabhi Dangi-Garimella, PhD

The improved expansion of chimeric antigen receptor (CAR) T-cells indicates a deeper clinical response.

January 18th 2017

Getting Insured Could Reduce Cancer-Related Deaths Among Minorities

Surabhi Dangi-Garimella, PhD

A new report released by the American Cancer Society indicates that while the cancer-related death rate was higher among blacks than in whites in 2014, the racial gap could reduce as minority patients increasingly gain access to insurance and subsequent healthcare.

January 18th 2017

RESONATE-2 Continues to Impress With Single-Agent Ibrutinib for CLL/SLL at 29 Months

Surabhi Dangi-Garimella, PhD

Despite the complexities associated with treating older patients diagnosed with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), patients in the RESONATE-2 trial continue to present a favorable response to single-agent ibrutinib at a follow-up of 29 months.

January 18th 2017

Phase 3 GALLIUM Study Shows Promising Results With Obinutuzumab for Follicular Lymphoma

Christina Mattina

The results showed that obinutuzumab-based immunochemotherapy and maintenance improved progression-free survival in treatment-naÃ¯ve patients with follicular lymphoma.

January 18th 2017

Ibrutinib Prevents Cytokine-Release Syndrome After CAR T-Cell Therapy for B-Cell Neoplasms

Christina Mattina

A study in a mouse model found that mice receiving chimeric antigen receptor (CAR)-T immunotherapy plus ibrutinib demonstrated longer overall survival and reduced cytokine production than the mice not treated with ibrutinib.

January 18th 2017

Dr Stuart Goldberg Explains Differences Between COTA and Traditional Data Analysis Tools

Data from electronic health records aren’t always helpful for oncologists, which is why the founders of Cancer Outcomes Tracking and Analysis (COTA) developed a platform that stratifies patients by relevant characteristics, said Stuart Goldberg, MD, chief medical officer, COTA, John Theurer Cancer Center.

January 17th 2017

MYSTIC Trial, Evaluating Durvalumab as First-Line in NSCLC, Adds OS Endpoint

Surabhi Dangi-Garimella, PhD

The trial, evaluating the programmed death ligand-1 inhibitor durvalumab, alone or in combination with tremelimumab, versus platinum-based chemotherapy, has refined its endpoints to include overall survival (OS) along with progression-free survival.

January 16th 2017

Cisplatin-Based Chemotherapy Increases Risk of Venous Thromboembolism

AJMC Staff

According to a new study, in addition to tumor type, stage, and the presence of comorbidities, patients receiving cisplatin-based treatments might be at an increased risk of venous thromboembolism.

January 16th 2017

The Value of Survival Gains in Myelodysplastic Syndromes

Joanna P. MacEwan, PhD Wes Yin, PhD Satyin Kaura, MSci, MBA Zeba M. Khan, PhD

This study measured the value of survival gains attributable to the introduction of 3 novel therapies for myelodysplastic syndromes.

January 16th 2017

Cytokine Biomarkers Can Predict Response to CAR T-Cell Treatment in CLL

Surabhi Dangi-Garimella, PhD

At the 58th American Society of Hematology Annual Meeting & Exposition, Jan Joseph Melenhorst, PhD, presented results of a study evaluating biomarkers of response to anti-CD19 CAR T-cell treatment in patients diagnosed with chronic lymphocytic leukemia (CLL).

January 16th 2017

Phase 3 LyMa Trial: Rituximab After ASCT Increases OS in Mantle Cell Lymphoma

Surabhi Dangi-Garimella, PhD

Phase 3 results from the LyMa trial have shown that rituximab, after autologous stem cell transplant (ASCT), prolongs event-free survival, progression-free survival, and overall survival (OS) in previously untreated young patients with mantle cell lymphoma (MCL) following ASCT.

January 16th 2017

Early Results Show Palbociclib Helps Sustain Patient Response to Ibrutinib in MCL

Surabhi Dangi-Garimella, PhD

Early phase 1 results show that including the cyclin-dependent kinase 4/6 inhibitor palbociclib in the treatment plan of patients with mantle cell lymphoma can help overcome resistance to ibrutinib.

January 16th 2017

CAR-T Cells of Defined Composition Effective in Ibrutinib-Refractory CLL

Surabhi Dangi-Garimella, PhD

In high-risk patients with chronic lymphocytic leukemia (CLL), CD19 chimeric antigen receptor (CAR)-T cells of defined composition can be administered with an acceptable early toxicity.

January 16th 2017

Patient and Provider Education on Pain in Cancer: A Cost-Saving Intervention

Surabhi Dangi-Garimella, PhD

An experiment by Park Nicollet Health Services to document personalized pain management goals for patients in oncology clinics lowered documented pain, while physician education on cost information helped reduce treatment costs.

January 16th 2017

Dr Robert Carlson on Balancing Efficiency and Patient-Centered Care

Oncologists need to ask patients the right questions and truly listen to the answers, but they must then balance the individuals’ goals with the practice’s efforts to provide consistently efficient cancer care to all patients, according to Robert W. Carlson, MD, CEO of the National Comprehensive Cancer Network.

January 15th 2017

Will Absence of Certain Cancer Centers on Insurance Exchanges Impact Outcomes?

Surabhi Dangi-Garimella, PhD

A new study conducted at The University of Texas has found that a majority of federal exchanges do not include National Cancer Institute-designated cancer centers.

January 14th 2017

David Fabrizio Suggests Advantages of Genomic Profiling for Payers

Payers have been slow to adopt new technologies, but they are starting to be more proactive in seeking out genomic profiling companies, according to David Fabrizio, of Foundation Medicine, Inc. These molecular diagnostic tools make the healthcare process more efficient by performing a comprehensive test at the point of diagnosis.

January 13th 2017

This Week in Managed Care: January 13, 2017

This week, the top stories in managed care were that the Senate began the process of repealing the Affordable Care Act, Cigna and CVS moved away from the EpiPen, and the NCI Formulary will make it easier to study cancer drugs and their combinations.

January 13th 2017

Trump Administration Can Use ASCO's Principles to Ensure Healthcare Remains Patient-Centered

Surabhi Dangi-Garimella, PhD

The American Society of Clinical Oncology (ASCO) hopes that the principles will help ensure access to healthcare and adequate insurance, to improve outcomes among those diagnosed with cancer.

January 12th 2017

The Burden of Being a Medicare Patient With NSCLC

Surabhi Dangi-Garimella, PhD

Research published in the Journal of Oncology Practice has identified high treatment burden among Medicare patients with early-stage non—small cell lung cancer (NSCLC).

January 12th 2017

Joint Statement by 69 Cancer Centers Supports CDC's HPV Vaccination Guideline

Surabhi Dangi-Garimella, PhD

A conglomerate of 69 National Cancer Institute—designated cancer centers has come together to endorse the CDC’s recommendations for HPV vaccination of young children.

January 11th 2017

NCI Formulary a Big Support for Cancer Moonshot

Surabhi Dangi-Garimella, PhD

Described as a public—private partnership between the National Cancer Institute (NCI) and pharmaceutical and biotechnology companies, the NCI Formulary is expected to provide researchers rapid access to anticancer drugs for use in clinical trials.

January 11th 2017

Dr Joseph Alvarnas on Importance of Patient Voice in Value-Based Cancer Care

The transformation to value-based oncology care must be centered upon the priorities and needs of patients and their families, said Joseph Alvarnas, MD, of the City of Hope and editor-in-chief of Evidence-Based Oncology. This vision is starting to be incorporated in areas like the Oncology Care Model, which looks at patient-reported outcomes and experiences.

January 10th 2017

Danish Study Rekindles Debate on Overdiagnosis of Breast Cancer

Surabhi Dangi-Garimella, PhD

A screening study conducted over 2 decades in Denmark has raised questions about the need and implications of biennial mammography for women between 50 and 69 years of age.

January 10th 2017

Reducing GVHD Following Transplant in Lymphoma

Surabhi Dangi-Garimella, PhD

Researchers from the Memorial Sloan Kettering Cancer Center have developed a novel method using modified donor T cells to make stem cell transplants both safer and more effective for treating blood cancers

January 9th 2017

JCO Study Identifies Increased Duration of Treatment in Medicare Patients With NSCLC

Surabhi Dangi-Garimella, PhD

The study observed significant shifts in the treatment of advanced-stage non-small cell lung cancer (NSCLC), accompanied by only modest gains in survival and total Medicare spending.

...

79 80 81 82 83 84 85 86 87

...

181 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions